Table 3.
Comparison of 2017 and 2022 European LeukmiaNet-acute myeloid leukemia risk classification
| Risk category | 2017 ELN | 2022 ELN |
|---|---|---|
| Favorable | t(8;21)(q22;q22.1);RUNX1-RUNX1T1 | t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 |
| inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 | inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 | |
| Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow* | Mutated NPM1 without FLT3-ITD | |
| Biallelic mutated CEBPA | bZIP in-frame mutated CEBPA | |
| Intermediate | Mutated NPM1 with FLT3-ITDhigh | Mutated NPM1 with FLT3-ITD |
| Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow (without adverse-risk genetic lesions) | Wild-type NPM1 with FLT3-ITD (without adverse-risk genetic lesions) | |
| t(9;11)(p21.3;q23.3)/MLLT3::KMT2A | t(9;11)(p21.3;q23.3)/MLLT3::KMT2A | |
| Cytogenetic abnormalities not classified as favorable or adverse | Cytogenetic and/or molecular abnormalities not classified as favorable or adverse | |
| Adverse | t(6;9)(p23.3;q34.10);DEK-NUP214 | t(6;9)(p23.3;q34.10)/DEK::NUP214 |
| t(v;11q23.3);KMT2A-rearranged | t(v;11q23.3)/KMT2A-rearranged | |
| t(9;22)(q34.1;q11.2);BCR-ABL1 | t(9;22)(q34.1;q11.2)/BCR::ABL1 | |
| t(8;16)(p11.2;p13.3)/KAT6A::CREBBP | ||
| inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM(EVI1) | inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EVI1) | |
| t(3q26.2;v)/MECOME(EVI1)-rearranged | ||
| -5 or del(5q); -7; -17/abn(17p) | -5 or del(5q); -7; -17/abn(17p) | |
| Complex karyotype, monosomal karyotype | Complex karyotype, monosomal karyotype | |
| Mutated RUNX1, ASXL1 | Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 | |
| Mutated TP53 | Mutated TP53 |
*FLT3: low Low allelic ratio (< 0.5), high High allelic ratio(≥ 0.5)